Amgen, Celgene and Pharmacyclics see short interest drop recently.
There's mixed interest in biotech, biopharmaceutical and emerging pharma companies.
This biotech company's Soliris drug shows promise in treating several rare, life threatening diseases.
Roche is upgraded to 'overweight,' while Novartis is downgraded to 'equal weight.'
Groupon is downgraded to 'equal weight,' while Isis Pharmaceuticals is upgraded to 'outperform.'
Tech, biotech and volatility funds are leading the way so far.
Autodesk is downgraded at 2 firms, and General Growth is downgraded to 'neutral.'
VIDEO ON MSN MONEY
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
TOP STOCKS
The outspoken hedge fund manager has left Twitter.
MARKET DISPATCHES
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
FRUGAL COOL
Starting Monday, this site is joining forces with MSN Money Smart Spending. Here's why.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
SMART SPENDING
Sounds too good to be true . . . but by using these extreme tactics, it's possible to save big at the pump.
SMART TAXES
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.
